|
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
The aim of this work was to assess the effect of long- and short-term incubation with daidzein, the second most abundant soy isoflavone and its metabolite equol on the expression and activity of P-glycoprotein, multidrug resistance-associated proteins 1 and 2 (MRP1 and MRP2) and BCRP in breast cancer cells.
|
29101532 |
2019 |
|
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Genes encoding proteins that have key functions in the DNA damage response, such as p53 and its inhibitors MDM2 and MDMX, are most likely candidates to harbor allelic variants that influence breast cancer susceptibility.
|
30956778 |
2019 |
|
Breast Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Over-expression of FSIP1 promotes breast cancer progression and confers resistance to docetaxel via MRP1 stabilization.
|
30814489 |
2019 |
|
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Expression of MDM2 and MDMX occurs in estrogen receptor α-positive (ERα<sup>+</sup>) breast cancer and triple-negative breast cancer (TNBC).
|
30642351 |
2019 |
|
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Contemplations, using the available literature, suggest that disrupting the stability and/or function of MDMX protein (and its downstream targets), in the context of mtp53 expressing BCs, might be beneficial for patient survival.
|
31489110 |
2019 |
|
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
This underscores the need for combinatorial approaches with focus on PXR antagonism to improve drug effectiveness in hepatocellular carcinoma.<b>Abbreviations:</b> HCC: Hepatocellular Carcinoma; FDA: Food and Drug Administration; TGF-β: Transforming growth factor-β; PXR: Pregnane X receptor; CAR: Constitutive androstane receptor; P-gp/ABCB1: P-glycoproteins/ATP-binding cassette transporter subfamily B member 1; MRP1/ABCC1 and MRP2/ABCC2: Multidrug-resistance associated proteins; BCRP/ABCG2: Breast cancer resistant protein; DMEs: Drug-metabolizing enzymes; CFDA: 5,6-carboxyfluorescein diacetate; ETS1: Transcription factor E26 transformation specific sequence 1.
|
31739702 |
2019 |
|
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Correlations of MRP1 gene with serum TGF-β1 and IL-8 in breast cancer patients during chemotherapy.
|
30570851 |
2019 |
|
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Mir-1307 regulates cisplatin resistance by targeting Mdm4 in breast cancer expressing wild type P53.
|
29697201 |
2018 |
|
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
The results showed that Que could increase intracellular accumulation of Dox in breast cancer cells through down-regulating the expression of efflux ABC transporters including P-gp, BCRP and MRP1, which can effectively eliminate cancerous cells including breast cancer stem cells (BCSCs), thereby potentiating the anti-tumor effect of Dox.
|
29475141 |
2018 |
|
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Expression of LRP Gene in Breast Cancer Patients Correlated with MRP1 as Two Independent Predictive Biomarkers in Breast Cancer
|
30486550 |
2018 |
|
Breast Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
linc00518 expression increased nearly 2 fold and MRP1 level elevated about 2.5 fold in breast cancer tissues as compared to that in adjacent normal tissues.
|
30001527 |
2018 |
|
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Our findings proposed that the MDM4 rs1380576 C>G polymorphism was a protective factor for BC risk in our population.
|
29439926 |
2018 |
|
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
The overexpression of ATP-binding cassette transporters (ABC transporters), mainly including permeability glycoproteins (P-gp), multidrug resistance (MDR)-related protein 1 (MRP1), and breast cancer resistance proteins (BCRP), is one of the main reasons for the development of MDR which directly leads to chemotherapy failure.
|
30197538 |
2018 |
|
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
The role of MDM2 and MDM4 in breast cancer development and prevention.
|
28096293 |
2017 |
|
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Even nontoxic dose of Tan IIA could also promote intracellular Dox accumulation of MCF-7 and MCF-7/dox cells through down-regulating the expression of efflux ABC transporters including P-gp, BCRP and MRP1, which can effectively eliminated cancerous cells including BCSCs, thereby enhancing the chemosensitivity of breast cancer.
|
29028589 |
2017 |
|
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
GWASCAT |
Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer.
|
27117709 |
2016 |
|
Breast Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Moreover, signaling pathways that mediate the overexpression of MDM4 in human breast cancer remain to be elucidated.
|
26909605 |
2016 |
|
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Based on our findings, we propose that Mdmx targeting is an attractive strategy for treating BrCas harboring wt p53.
|
26181202 |
2015 |
|
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Interaction between p53 mutation and a somatic HDMX biomarker better defines metastatic potential in breast cancer.
|
25649770 |
2015 |
|
Breast Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Recently, a 4-nitrobenzofuroxan derivative, XI-006 (NSC207895) was shown to diminish MDM4 promoter activity in breast cancer cell lines.
|
26095524 |
2015 |
|
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We conclude, MDM4 SNP34091 status to be associated with reduced risk of breast cancer, in particular in individuals carrying the MDM2 SNP309GG genotype, but not to be associated with either lung-, colon- or prostate cancer.
|
26471763 |
2015 |
|
Breast Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Here, we show that the EMT phenotype in multiple cellular models and in clinical prostate and breast cancer samples is associated with a decrease in MDM2 and increase in MDMX expression.
|
26416355 |
2015 |
|
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
GWASCAT |
Genome-wide association studies identify four ER negative-specific breast cancer risk loci.
|
23535733 |
2013 |
|
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Genetic variability in the multidrug resistance associated protein-1 (ABCC1/MRP1) predicts hematological toxicity in breast cancer patients receiving (neo-)adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide (FEC).
|
23396606 |
2013 |
|
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
CTD_human |
Genome-wide association studies identify four ER negative-specific breast cancer risk loci.
|
23535733 |
2013 |